Lodestar

MDLN

Medline Inc.
NasdaqSurgical & Medical Instruments & ApparatusLatest fiscal year ended Dec 31, 2025

Medline Inc. reported revenue of $28.43B in its most recent fiscal year. It kept 4.1% of that as net income, and generated $1.30B of free cash flow. Figures below are compared against other companies classified under Surgical & Medical Instruments & Apparatus.

Grades vs. industry

Profitability
B65/100
Ranked against 91 peers using 7 metrics.
Financial health
C46/100
Ranked against 34 peers using 5 metrics.

Growth

MetricCompanyIndustry medianRank
Revenue growth (YoY)
Latest fiscal year revenue vs. the year before.
Not reported14.2%—
Revenue growth (3y)
Annualized revenue growth over three fiscal years.
7.0%13.8%57 / 91
Revenue growth (5y)
Annualized revenue growth over five fiscal years.
Not reported15.3%—
EPS growth (YoY)
Diluted EPS vs. the prior fiscal year.
Not reported9.0%—
EPS growth (3y)
Annualized diluted EPS growth over three fiscal years.
Not reported17.1%—
EPS growth (5y)
Annualized diluted EPS growth over five fiscal years.
Not reported9.5%—
Free cash flow growth (YoY)
Operating cash flow less capital expenditure, vs. prior year.
Not reported5.7%—
Free cash flow growth (3y)
Annualized free cash flow growth over three fiscal years.
-2.7%25.6%15 / 20

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Profitability

MetricCompanyIndustry medianRank
Gross margin
Gross profit as a share of revenue. Often unreported.
26.4%61.6%94 / 102
Operating margin
Operating income as a share of revenue.
7.8%-12.3%26 / 94
Net margin
Net income as a share of revenue.
4.1%-17.8%29 / 98
Free cash flow margin
Free cash flow as a share of revenue.
4.6%-4.4%28 / 91
Return on equity
Net income divided by shareholder equity.
10.8%-28.8%22 / 110
Return on assets
Net income divided by total assets.
3.0%-18.3%30 / 120
Return on invested capital
After-tax operating profit over debt plus equity less cash.
9.6%-20.9%23 / 94

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Financial health

MetricCompanyIndustry medianRank
Debt to equity
Total debt divided by shareholder equity.
1.17x0.45x47 / 63
Current ratio
Current assets over current liabilities.
4.29x3.31x46 / 120
Quick ratio
Current assets excluding inventory, over current liabilities.
2.37x2.49x63 / 120
Interest coverage
Operating income divided by interest expense.
2.34x-4.86x20 / 73
Net debt to EBITDA
Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed.
3.30x0.61x28 / 34

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Debt figures can be understated where a filer splits borrowings across XBRL tags this site does not match.

Insider activity

Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 17 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.

DateInsiderTransactionSharesPriceValue
Oct 8, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale7,816,987$35.15$274.77M
Oct 6, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale7,183,013$35.05$251.76M
Oct 6, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale2,088,987$35.05$73.22M
Oct 5, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale1,688,690$35.78$60.42M
Oct 2, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale7,146,941$34.33$245.35M
Oct 2, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale2,570,999$35.35$90.88M
Aug 19, 2026
Boyle James M
Chief Executive Officer
Grant or award(derivative)764,252——
Aug 19, 2026
Miller Stephen L
Chief Operating Officer
Grant or award(derivative)87,667——
Aug 14, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale100,000$35.80$3.58M
Aug 13, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale1,500,000$35.80$53.70M
Aug 7, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale590,284$35.58$21.00M
Aug 6, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale271,994$35.33$9.61M
Aug 6, 2026
Mozart Holdco, Inc.
10% owner
Conversion500,000$0.00$0.00
Aug 6, 2026
Mozart Holdco, Inc.
10% owner
Other500,000$0.00$0.00
Aug 6, 2026
Mozart Holdco, Inc.
10% owner
Conversion(derivative)500,000$0.00$0.00
Aug 5, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale1,710,907$35.46$60.67M
Aug 5, 2026
GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd.
10% owner
Open-market sale265,711$36.48$9.69M

A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.

Annual financials

Fiscal year2025 Dec2025 Dec20242023
Revenue$28.43B—$25.51B$23.23B
Gross profit$7.52B—$6.98B$5.88B
Operating income$2.21B—$2.15B$1.25B
Net income$1.16B$1.15B$1.16B$234.00M
EPS (diluted)-$0.01———
Operating cash flow$1.74B—$1.77B$1.69B
Capital expenditure$447.00M—$354.00M$275.00M
Free cash flow$1.30B—$1.42B$1.41B
Total assets$38.48B—$35.98B—
Shareholder equity$10.74B———
Total debt$12.56B—$16.49B—
Cash$1.94B—$199.00M$1.58B

A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.

Source

Figures come from Medline Inc.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Feb 25, 2026. View filings on EDGAR.

Not financial advice. This page presents figures reported to the SEC and compares them with other companies sharing an industry classification. It is not a recommendation to buy or sell anything, and the grades cannot capture everything that matters about a business. Industry classifications are coarse, filings are self-reported, and some figures are missing or understated where companies tag them in ways this site does not match. Do your own research.